Edesa Biotech Inc (EDSA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Edesa Biotech Inc (EDSA) has a cash flow conversion efficiency ratio of -0.346x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.05 Million) by net assets ($8.81 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see EDSA company net worth for the company's overall valuation and market capitalisation.
Edesa Biotech Inc - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Edesa Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Edesa Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Edesa Biotech Inc ranked by their cash flow conversion efficiency. Explore Edesa Biotech Inc cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Epitomee Medical Ltd
TA:EPIT
|
-0.416x |
|
Staatl. Mineralbrunnen AG
MU:SLB
|
N/A |
|
White Cliff Minerals Ltd
AU:WCN
|
-0.510x |
|
Novacyt
PA:ALNOV
|
-0.141x |
|
Aerodrome Group Ltd
TA:ARDM
|
-0.166x |
|
Chin Yang Ind
KO:003780
|
-0.012x |
|
Granprade
JSE:GPL
|
-0.020x |
|
Wijaya Karya Beton
JK:WTON
|
0.038x |
Annual Cash Flow Conversion Efficiency for Edesa Biotech Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of Edesa Biotech Inc from 2009 to 2025. View current stock price of Edesa Biotech Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $12.45 Million | $-7.32 Million | -0.588x | +76.18% |
| 2024-09-30 | $1.98 Million | $-4.89 Million | -2.468x | -162.17% |
| 2023-09-30 | $7.05 Million | $-6.64 Million | -0.942x | +27.99% |
| 2022-09-30 | $9.39 Million | $-12.28 Million | -1.308x | -24.95% |
| 2021-09-30 | $13.06 Million | $-13.66 Million | -1.046x | -91.15% |
| 2020-09-30 | $9.11 Million | $-4.99 Million | -0.547x | +40.62% |
| 2019-09-30 | $5.26 Million | $-4.85 Million | -0.922x | -125.45% |
| 2018-09-30 | $11.29 Million | $-4.62 Million | -0.409x | +35.62% |
| 2017-09-30 | $7.40 Million | $-4.70 Million | -0.635x | -73.60% |
| 2016-09-30 | $12.31 Million | $-4.51 Million | -0.366x | +33.62% |
| 2015-09-30 | $8.01 Million | $-4.41 Million | -0.551x | +0.52% |
| 2014-09-30 | $7.70 Million | $-4.27 Million | -0.554x | -159.51% |
| 2013-09-30 | $-3.14 Million | $-2.92 Million | 0.931x | +120.08% |
| 2012-09-30 | $851.61K | $-3.95 Million | -4.636x | -713.47% |
| 2011-09-30 | $4.59 Million | $-2.62 Million | -0.570x | -92.42% |
| 2010-09-30 | $2.47 Million | $-732.23K | -0.296x | -281.29% |
| 2009-09-30 | $484.95K | $-37.67K | -0.078x | -- |
About Edesa Biotech Inc
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-… Read more